Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.

Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who were either treatment-naïve (TN) or had relapsed/refractory (R/R) disease. Patients had disease requiring treatment per International Workshop on Waldenström Macroglobulinemia (IWWM) criteria.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently exhibiting synergy with the alkylating agent melphalan (Sanchez et al., Leuk Res 35(3):373-379, 2011). This phase 1/2 trial investigated the safety and efficacy of panobinostat in combination with melphalan for relapsed/refractory multiple myeloma patients.

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.

The combination of pegylated liposomal doxorubicin (PLD), bortezomib and dexamethasone has shown efficacy in the treatment of multiple myeloma (MM) patients. Our earlier retrospective study suggested that modification of the doses, schedules and route of administration of these drugs appears to reduce toxicity without compromising anti-MM activity. As a result, we evaluated this modified drug combination in the frontline setting in a prospective multicentre phase II trial.

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.

Few studies have evaluated prognostic factors among patients with multiple myeloma (MM) since new therapies have become available. Monthly zoledronic acid (ZOL) has been incorporated into many treatment regimens to reduce skeletal-related events (SREs), but outcomes among patients receiving this bisphosphonate have not been well-defined. The aim of this retrospective study was to determine baseline and on-treatment prognostic factors in these patients.

A unified model of illusory and occluded contour interpolation.

Models of contour interpolation have been proposed for illusory contour interpolation but seldom for interpolation of occluded contours. The identity hypothesis (Kellman & Loukides, 1987; Kellman & Shipley, 1991) posits that an early interpolation mechanism is shared by interpolated contours that are ultimately perceived as either illusory or occluded. Here we propose a model of such a unified interpolation mechanism for illusory and occluded contours, building on the framework established in Heitger, von der Heydt, Peterhans, Rosenthaler, and Kubler (1998).

Surface interpolation and 3D relatability.

Although the role of surface-level processes has been demonstrated, visual interpolation models often emphasize contour relationships. We report two experiments on geometric constraints governing 3D interpolation between surface patches without visible edges. Observers were asked to classify pairs of planar patches specified by random dot disparities and visible through circular apertures (aligned or misaligned) in a frontoparallel occluder.